Vall d’Hebron Institute of Oncology (VHIO)

Developed by VHIO, a novel AI-based and non-invasive diagnostic tool enables accurate brain tumour diagnosis, outperforming current classification methods

Developed by VHIO’s Radiomics Group in close collaboration with researchers of the Neuro-Radiology Unit at the Bellvitge University Hospital (HUB), DISCERN is a deep learning tool that leverages information of magnetic resonance imaging and facilitates brain tumour classification to aid clinical decision making Currently, a definitive diagnosis often requires neurosurgical interventions that compromise the quality...

Immunotherapy added to first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

Published in The Lancet, results of the randomised phase 3 BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint inhibitor atezolizumab to standard of care with bevacizumab and chemotherapy significantly improves progression-free survival and overall survival in patients with metastatic or recurrent cervical cancer who are not candidates for curative-intent surgery and/or radiotherapy. This...
C/ Natzaret, 115-117 08035 – BARCELONA – Spain

+34 93 254 34 50